Ani Pharmaceuticals (ANIP) Equity Ratio (2019 - 2023)

Ani Pharmaceuticals (ANIP) has 5 years of Equity Ratio data on file, last reported at 0.44 in Q1 2023.

• For the quarter ending Q1 2023, Equity Ratio fell 4.52% year-over-year to 0.44; the trailing twelve-month figure through Mar 2023 stood at 0.44 (down 4.52% YoY), and the FY2022 full-year result was 0.45, down 4.2% from the prior year.
• Equity Ratio was little changed at 0.44 in Q1 2023, from 0.45 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.47 in Q4 2019 to a low of 0.4 in Q2 2021.
• A 5-year average of 0.44 and a median of 0.45 in 2022 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio retreated 8.91% in 2020 and climbed 12.21% in 2022, its largest moves.
• Tracing ANIP's Equity Ratio over 5 years: stood at 0.47 in 2019, then dropped by 8.91% to 0.42 in 2020, then advanced by 9.57% to 0.46 in 2021, then slipped by 4.2% to 0.45 in 2022, then retreated by 0.39% to 0.44 in 2023.
• Business Quant data shows ANIP's Equity Ratio at 0.44 in Q1 2023, 0.45 in Q4 2022, and 0.46 in Q3 2022.